What is KYMRIAH? KYMRIAH is made from your own white blood cells and is a prescription cancer treatment used in patients up to 25 years of age who have acute lymphoblastic leukemia (ALL) that is either relapsing (went into remission, then came back) or is refractory (did not go into remission after receiving other leukemia treatments).

CAR-T 是一种癌症免疫治疗技术，全称为“嵌合抗原受体T细胞治疗”，是利用患者自身的T细胞，通过基因工程技术改造，使其能够识别并攻击癌细胞。 截止目前已经有4款靶点 CD19 的CAR-T药物上市，分别为： KYMRIAH® Tisagenlecleucel (Tisa-cel)，作为第一款上市的CAR-T药物，由 Novartis 公司开发，2017年获FDA批准上市。 尚未在国内引进，音译为替基仑赛（无出处）； YESCARTA® Axicabtagene ciloleucel (Axi-cel) （奕凯达®阿基仑赛）。 由吉利德旗下Kite公司 …

Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer (adoptive cell transfer).

Kymriah是美国FDA批准的第一个CAR-T细胞疗法， 目前在全球30个国家上市，有超过350个认证的治疗中心。 Kymriah是一种CD19导向的基因修饰自体T细胞免疫 ...

近日，美国食品和药品管理局（FDA）批准 诺华 的CAR-T药物 Kymriah 用于治疗患有复发或难治性大B细胞淋巴瘤的成年患者，其中包括弥漫性大B细胞淋巴瘤、高度B细胞淋巴瘤和滤泡性淋巴瘤引起的弥漫性大B细胞淋巴瘤。这是Kymriah获批的第二个适应症。 什么是 CAR-T疗法

KYMRIAH® (tisagenlecleucel) is a type of immunotherapy for patients with relapsed or refractory (r/r) B-cell ALL. Discover how KYMRIAH works, what makes it different from other therapies, and whether it could be right for you. KYMRIAH is available at select treatment centers across the …

Kymriah是一种CAR-T的免疫细胞疗法，由宾夕法尼亚大学和诺华公司共同研发的革命性免疫细胞疗法。 2017年8月，Kymriah已通过美国食品和药物管理局（FDA）的正式上市批准。

2018年9月19日 · Kymriah is a medicine for treating the following types of blood cancer: • B-cell acute lymphoblastic leukaemia (ALL), in children and young adults up to 25 years of age whose cancer did not respond to previous treatment, has come back two or more times, or has come back after a transplant of stem cells;

KYMRIAH is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of: • Patients up to 25 years of age with B-cell precursor acute lymphoblastic

2023年12月31日 · Kymriah® (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, is currently approved in major markets for the treatment of relapsed/refractory (r/r) pediatric and young adult acute lymphoblastic leukemia, r/r diffuse large B-cell lymphoma, and r/r follicular lymphoma.